Canagliflozin is under clinical development by Johnson & Johnson and currently in Phase III for Systolic Heart Failure. According to GlobalData, Phase III drugs for Systolic Heart Failure have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Canagliflozin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Canagliflozin overview

Canagliflozin (Invokana/ Prominad/Canaglu/ Motivyst/Sulisent ) a drug of the gliflozin class and an antidiabetic drug. It is formulated as film-coated tablets for oral route of administration. It is indicated for the treatment of type 2 diabetes mellitus. It is also indicated for the use in combination with metformin and sitagliptin in adults with type 2 diabetes mellitus, and reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria 300 mg/day. Canaglu is indicated for the treatment of chronic kidney disease complicated with type 2 diabetes mellitus.

The drug candidate is under development for the treatment of heart failure with preserved ejection fraction in type 2 diabetes mellitus, symptomatic heart failure (HF) including heart failure with reduced ejection fraction [HFrEF] and heart failure with preserved ejection fraction [HFpEF], diabetic nephropathy. It was also under development for type 1 diabetes, cardiovascular disease in type 2 diabetes patients and obesity.

Johnson & Johnson overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

For a complete picture of Canagliflozin’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.